ID   NCC-GCTB16-C1
AC   CVCL_F6LH
RX   PubMed=41801630;
CC   Part of: NCC sarcoma cell line panel.
CC   Population: Japanese.
CC   Characteristics: Can form spheroids (PubMed=41801630).
CC   Doubling time: ~25 hours (PubMed=41801630).
CC   Sequence variation: Mutation; HGNC; HGNC:4764; H3-3A; Simple; p.Gly35Trp (c.103G>T) (G34W); Zygosity=Heterozygous (PubMed=41801630).
CC   Omics: Proteomics; Quantitative.
CC   Derived from site: In situ; Bone, right distal femur; UBERON=UBERON_0004406.
ST   Source(s): PubMed=41801630
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D13S317: 11
ST   D16S539: 9,11
ST   D21S11: 28,29
ST   D5S818: 9,11
ST   D7S820: 11,12
ST   TH01: 6,9
ST   TPOX: 8
ST   vWA: 17,18
DI   NCIt; C4304; Malignancy in giant cell tumor of bone
DI   ORDO; Orphanet_363976; Giant cell tumor of bone
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   28Y
CA   Cancer cell line
DT   Created: 22-10-26; Last updated: 22-10-26; Version: 1
//
RX   PubMed=41801630; DOI=10.1007/s13577-026-01363-7;
RA   Kono, Kenta
RA   Shiota, Yomogi
RA   Osaki, Julia
RA   Shu, Ting-Ting
RA   Kamio, Satoshi
RA   Iwata, Shintaro
RA   Nishino, Shogo
RA   Yoshida, Akihiko
RA   Ohtsuki, Sumio
RA   Ohtori, Seiji
RA   Kawai, Akira
RA   Kondo, Tadashi
RT   "Establishment and characterization of NCC-GCTB16-C1: novel
RT   patient-derived cell line of giant cell tumor of bone.";
RL   Hum. Cell 39:51-51(2026).
//